A New Indirect Chemiluminescent Immunoassay to Measure Anti–tissue Transglutaminase Antibodies

2006 ◽  
Vol 43 (5) ◽  
pp. 613-618 ◽  
Author(s):  
Daniela Basso ◽  
Graziella Guariso ◽  
Michela Fasolo ◽  
Marina Pittoni ◽  
Stefania Schiavon ◽  
...  
2020 ◽  
Vol 71 (2) ◽  
pp. 45-51
Author(s):  
Oana Belei ◽  
Emil Radu Iacob ◽  
Daniela Iacob ◽  
Elena Amaricai ◽  
Otilia Marginean

Recent describing of atypical, silent and latent form of celiac disease (CD) increased the preocupation for screening methods.To perform a comparative study of immunoglobulin A (IgA) anti tissue-transglutaminase (tTG) antibodies (Ab) assessment using chemiluminescence versus Enzyme Linked Immunosorbent Assay (ELISA).The study included two lots.The first lot consisted in 35 biopsy confirmed CD children aged between two and 18 years.The control lot included 40 children with normal duodenal morphology on intestinal biopsy that underwent upper digestive endoscopy for different gastrointestinal symptoms.Serum samples were provided from all subjects for IgA measurement, IgA anti tTG and EMA assessment. Immulite 2500 Anti tTG IgA (Siemens Co, LA, USA) and ImmuLisa anti-hu tTG antibody IgA ELISA (Immco Diagnostics Inc, NY, USA) kits were used for tTG-Ab assessment. All children underwent HLA typing for DQ2/DQ8. The sensitivity for IgA tTG assessment was greater for chemiluminescence (93,3%) versus ELISA (86,6%), p[0,05, while specificity, positive and negative predictive value didn�t register significant differences. Statistical comparison of the two tested methods revealed a better sensitivity for chemiluminescence. Diagnosis algorithm optimisation may be obtained by associating IgA anti tTG-Ab assessment using chemiluminescence followed by EMA confirmation by indirect immunofluorescence for CD screening.


2021 ◽  
Vol 56 (4) ◽  
pp. 378-381
Author(s):  
Necati Balamtekin ◽  
Harun Erdal ◽  
Emira Gençkardeşler ◽  
Melike Arslan

2006 ◽  
Vol 20 (5) ◽  
pp. 184-189 ◽  
Author(s):  
N. Bizzaro ◽  
M. Tampoia ◽  
D. Villalta ◽  
S. Platzgummer ◽  
M. Liguori ◽  
...  

2018 ◽  
Vol 36 (5) ◽  
pp. 369-376 ◽  
Author(s):  
Nurit Loberman-Nachum ◽  
Michael Schvimer ◽  
Camila Avivi ◽  
Iris Barshack ◽  
Avishay Lahad ◽  
...  

Background: The clinical, histological, and serological spectrum of celiac disease (CD) vary widely. We aimed to examine relationships between symptoms, serum anti-tissue transglutaminase antibodies (tTG) levels, mucosal damage, and mucosal anti-tTG deposits in pediatric CD. Methods: A retrospective single-center, cohort study of children referred for endoscopy with suspected CD during 2011–2014. We retrieved the clinical data, blindly reviewed duodenal biopsies, and performed immunohistochemical staining for anti-tTG deposits. Patients were classified as monosymptomatic or polysymptomatic. Mucosal anti-tTG deposits were classified according to the location of deposits, dominant intensity, maximal intensity, and percentage of stained area. Results: Of 252 patients with confirmed CD, complete data were available for 100: 37 males in the age range 1.3–16.7 with median 4.0 years. Monosymptomatic patients (n = 54) presented at an older age than polysymptomatic patients (1.3–15.5, median 8.1 vs. 1.3–16.7, median 6.3 years, p = 0.026). Marsh 2–3c was more prevalent in polysymptomatic patients (93 vs. 78%, p = 0.028). The intensity of mucosal anti-tTG deposits correlated with serum anti-tTG levels but not with the clinical presentation. Conclusions: Multiple symptoms and high serum anti-tTG antibody levels correlated with mucosal damage in children with CD. The role of immunohistochemical staining for intestinal anti-tTG mucosal deposits in the diagnosis of borderline CD is not yet established.


2017 ◽  
Vol 65 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Anna K. Le Fevre ◽  
Marjorie M. Walker ◽  
Amir Hadjiashrafy ◽  
Rani Bhatia ◽  
Joerg Mattes ◽  
...  

Nutrients ◽  
2018 ◽  
Vol 10 (7) ◽  
pp. 892 ◽  
Author(s):  
Iva Hoffmanová ◽  
Daniel Sánchez ◽  
Ludmila Tučková ◽  
Helena Tlaskalová-Hogenová

Immunologically mediated liver diseases belong to the common extraintestinal manifestations of celiac disease. We have reviewed the current literature that addresses the association between celiac disease and liver disorders. We searched relevant articles on MEDLINE/PubMed up to 15 June 2018. The objective of the article is to provide a comprehensive and up-to-date review on the latest hypotheses explaining the pathogenetic relationship between celiac disease and liver injury. Besides the involvement of gut–liver axis, tissue transglutaminase antibodies, and impairment of intestinal barrier, we integrate the latest achievements made in elucidation of the role of gut microbiota in celiac disease and liver disorders, that has not yet been sufficiently discussed in the literature in this context. The further objective is to provide a complete clinical overview on the types of liver diseases frequently found in celiac disease. In conclusion, the review highlights the clinical implication, recommend a rational approach for managing elevated transaminases in celiac patients, and underscore the importance of screening for celiac disease in patients with associated liver disease.


Sign in / Sign up

Export Citation Format

Share Document